• Resources & Support

• Hep B Birth Dose Media Toolkit
• Immunization Awareness Month
• Our Blog
• 
  Patient and Provider Opportunities
  • Grifols clinical trial
• Hepatitis B Foundation's Discrimination Registry
• 
  Know Your Rights
  • U.S. Schools and Education
  • U.S. Employment
  • U.S. Military
  • U.S. Access to Medication
  • U.S. Public Health Corps
  • Immigration and International Issues
• Online Support Groups
• Fact Sheets
• 
  Online Training
  • Hepatitis B ECHO Hubs
  • Hepatitis B Online Lessons
• Glossary
• B Informed Conference Videos and Information
• 
  Patient-facing infographics
  • The Physical Toll of Living with Hepatitis B
  • The Social impact of Living With Hepatitis B
  • Worrying About Disease Progression
  • Worrying About Disease Transmission
  • Importance of Hepatitis B Screening
  • What People Want: The Most Important Outcomes of Future Hepatitis B Treatments
• B Heppy Podcast

Grifols clinical trial

A clinical research study is now enrolling adults with chronic hepatitis B virus.

Grifols is currently recruiting participants for a clinical trial for a new treatment for chronic hepatitis B virus infection. The purpose of this clinical trial is to evaluate the safety and tolerability of a single IV (intravenous) dose in part one and six  IV infusions in part two of GIGA-2339 in participants with chronic HBV infection.

Your participation could contribute to research that may improve future treatment options for chronic hepatitis B. 

You may be eligible to participate if you:

• Are 18+ years of age and
• Have been diagnosed with chronic HBV infection.

GIGA-2339 is an investigational drug that is designed to eliminate the hepatitis B virus particles from the blood that prevent a person’s immune system from fighting the virus. This can potentially allow the body to gain control over the infection.

The study will be conducted in two parts.

• In Part 1 a single infusion of GIGA-2339 will be given by IV and
• In Part 2 six infusions of GIGA-2339 will be given by IV every 4 weeks over the course of 6 months.

Participants will be required to stay overnight for at least 24 hours to monitor their safety and to collect blood samples after each IV infusion in both Part 1 and Part 2.

If you qualify and choose to enroll, you will be asked to attend scheduled clinic visits over a period of 105 Days for Part 1 and 245 days for Part 2.  

Study-related tests may include among other assessments:

• Blood draws,
• ECG (electrocardiogram) and
• Liver ultrasound. 

Study-related procedures and medications associated with this clinical trial will not result in expenses or charges to participants. Compensation for time and travel expenses may be provided.   

Clinical trials provide a great opportunity to help advance hepatitis B research and give people with hepatitis B access to new treatments. To find out more information and see if you qualify, please send an email to the specific site you are interested in participating at [see the list below]. 

State:	City:	Contact information:
Arizona	Chandler, AZ, U.S.	lgutierrez@azclinicaltrials.com
California	Huntington Beach, CA, U.S.	mcampos@marvelclinical.com
California	Lake Forest, CA, U.S.	PatientCare@OCResearchCenter.com
California	Long Beach, CA, U.S.	info@longbeachresearch.com
California	Oakland, CA, U.S.	Libnir@theoaklandinstituteofhealthinc.com
Georgia	Peachtree Corners, GA, U.S.	jhemphill@acceleratedclinicaltrials.org
Iowa	Iowa City, IA, U.S.	julie-szewc@uiowa.edu
Kansas	Lenexa, KS, U.S.	recruitingdep@jcct.com
Maryland	Baltimore, MD, U.S.	sawad3@jhu.edu
Virginia	Richmond, VA, U.S.	sara.oconnor@vcuhealth.org
Texas	San Antonio, TX, U.S.	rscarboro@txliver.com
Texas	Webster, TX, U.S.	sc@tranquilityresearch.com

Disclaimer: Participation in this trial is completely voluntary. Your decision will not affect the medical care you receive now or in the future. Your privacy and confidentiality will be strictly maintained.